

JC20 Rec'd PCT/PTO 20 JUN 2005

INFORMATION DISCLOSURE  
CITATION

(Use several sheets if necessary)

Atty. Docket No.

20-368

Applicant

STEVENS et al.

Filing Date

June 20, 2005

Serial No.

unk

10/539451

TC/A.U.

unknown

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,391,570 A	02/1995	CATT et al.			
	6,153,611	11/2000	Mattson et al.			

## FOREIGN PATENT DOCUMENTS

						TRANSLATION	
DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
03 004479 A	01/2003	WO					
0 469 984 A	02/1992	EP					
WO 01/92239	12/2001	WO					
EP 0 546 583	12/1992	EP					

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE  
CITATION

(Use several sheets if necessary)

Atty. Docket No.

Serial No.

20-368

unl. wh

10/539451

Applicant

STEVENS et al.

Filing Date

TC/A.U.

June 20, 2005

unknown

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	International Search Report of PCT/GB02/05842, mailed April 2, 2003
	Alcaraz, L., et al., 1998, "Manumycin A: synthesis of the (+)-enantiomer and revision of stereochemical assignment," <i>J. Org. Chem.</i> , Vol. 63, pp. 3526-3527.
	Alley et al., 1988, "Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay," <i>Cancer Research</i> , Vol. 48, p. 589.
	Boyd, M.R., Paull, K.D., 1995, "Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery system," <i>Drug Dev. Res.</i> , Vol. 34, pp. 91-104.
	Callinan et al., 1990, "Spiro-annulated 2,5-cyclohexadienones via oxidation of 2'-alkenyl-p-phenyl phenols with iodobenzene diacetate," <i>Tetrahedron Letters</i> , Vol. 31, No. 32, pp. 4551-4552.
	Capparelli et al., 1987, "Structural and solvent/electrolyte effects on the selectivity and efficiency of the anodic oxidation of para-substituted aromatic ethers. An efficient route to quinol ether ketals and quinol ethers," <i>J. Org. Chem.</i> , Vol. 52, pp 4953-4961.
	Collins, L.; Franzblau, S.G.; 1997, "Microplate Alamar Blue Assay versus BACTEC 460 System for High-throughput Screening of Compounds against <i>Mycobacterium tuberculosis</i> and <i>Mycobacterium avium</i> ," <i>Antimicrob. Agents Chemother.</i> , Vol. 41, pp. 1004-1009.
	Dengler et al., 1995, "Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays," <i>Anti-cancer drugs</i> , Vol. 6, pp. 522-532.
	Dodge, J.A., et al., 1988, "Competitive dienone-phenol type rearrangements for the regioselective preparation of 2,4-disubstituted-naphth-1-ols," <i>Tetrahedron Letters</i> , Vol. 29, No. 38, p. 4827-4830.
	Faaland et al., 1991, "Rapid uptake of tyrphostin into A431 human epidermoid cells is followed by delayed inhibition of epidermal growth factor (EGF) stimulated EFG receptor tyrosine kinase activity," <i>Mol. Cell Biol.</i> , Vol. 11, pp. 2697-2703.
	Gasdaska et al., 1994, "The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived cofactor (ADF): thioredoxin mRNA is elevated in some human tumors," <i>Biochimica et Biophysica Acta</i> , Vol. 1218, p. 292.
	Geran et al., 1972, "Protocols for screening chemical agents and natural products against tumor and other biological systems," <i>Cancer Chemother. Rep.</i> , Vol. 3, p. 1-103.
	Hutchinson et al., 2001, Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluoroinated 2-(4-aminophenyl)benzothiazoles," <i>J. Med. Chem.</i> , Vol. 44, pp. 1446-1455.
	Kirkpatrick et al., 1999, "Parallel synthesis of disulfide inhibitors of the thioredoxin redox system as potential antitumor agents," <i>Anti-Cancer Drug Design</i> , Vol. 14, pp. 421-432.
	Kunkel et al., 1997, "Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs," <i>Anti-Cancer Drug Design</i> , Vol. 12, pp. 659-670.
	McKillop et al., 1993, "A concise synthesis of the novel antibiotic aranorin," <i>Tetrahedron Lett.</i> , Vol. 34, pp. 5519-5522.
	Milić, D. R., et al., "X-Ray crystal structure of 10 $\beta$ -hydroxy-4 $\beta$ ,5 $\beta$ -epoxyestr-1-en-3,17-dione and antitumor activity of its congeners," <i>Molecules</i> , Vol. 4, pp. 338-352.
	Oblong et al., 1993, "Purification of human thioreductase; properties and characterization by absorption and circular dichroism spectroscopy," <i>Biochemistry</i> , Vol. 32, p. 7271.
	Pelter, A., Elgendy, S.M.A., 1993, "Phenolic oxidations with phenyliodonium diacetate," <i>J. Chem. Soc., Perkin Trans. 1</i> , pp. 1891-1896.
	Powis, G., Mustacich, D., Coon, A., 2000, "The role of the redox protein thioredoxin in cell growth and cancer," <i>Free Radical Biology &amp; Medicine</i> , Vol. 29, Nos. 3/4, pp. 312-322.
	Ramdas et al., 1994, "The degree of inhibition of protein tyrosine kinase activity by Tyrphostin 23 and 25 is related to their instability," <i>Cancer Research</i> , Vol 54, pp. 867-869.

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

**Atty. Docket No.**

Serial No.

**20-368**

Serial No. **101539451**

**Applicant**

STEVENS et al.

Filing Date

TC/A.U.

**June 20, 2005**

unknown

[illegible]

**\*Examiner**

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.